Home News and Events Press Release
Press Release
Stay up to date on Argo Biopharma’s latest news and events.
Stay up to date on Argo Biopharma’s latest news and events.
Stay up to date on Argo Biopharma’s latest news and events.
Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
Learn MoreArgo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
Learn MoreArgo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
Learn MoreArgo Biopharma Named to Fast Company's Annual List of the World’s Most Innovative Companies of 2026
Learn MoreArgo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
Learn MoreArgo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer
Learn MoreArgo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
Learn More
为了更好的呈现效果，移动端请竖屏浏览
